UNASSIGNED: e11001 Background: @entity9433 (L) is a @entity4149 kinase inhibitor (TKI) that has efficacy in @entity0 . This study assessed the cardiac safety of @entity9433 in @entity1 with cerbB-2 amplified metastatic @entity0 . METHODS: In this study, 26 @entity1 who were previously treated with @entity8253 , @entity6023 and trastuzumab were assigned to receive @entity9433 (L) plus @entity416 (C). @entity1370 was assessed with symptoms, transthoracic echocardiography, electrocardiography (ECG), @entity3876 ( @entity3876 ), @entity908 kinase (CK) and CK-MB at baseline and every 9 weeks until progression. RESULTS: A total of 26 @entity1 were treated with L+C for a median follow-up of 18 weeks. The median age was 48 (28-83) years. Among 25 eligible @entity1 , 8 (30,8%) had ECG changes one of which was grade I @entity1162 and 2 (7.7%) had decreased left ventricular ejection fraction (LVEF) below critical level (>15% drop compared to baseline or below normal level). Although there were no clinically observed cardiac symptoms, @entity9433 was stopped in one @entity1 who had decreased LVEF. The @entity1 showed recovery of LVEF after three cycles of @entity416 monotherapy. @entity9433 was restarted and L+C therapy was continued until progression. The other @entity1 who also had decreased LVEF, contiuned L+C therapy. LVEF normalized after 3 cycles of L+C combination therapy. Both @entity1 are alive without any @entity299 . The @entity1 with grade I @entity1162 continued the therapy and after 3 cycles QT distance turned to normal limits. Among eligible 21 @entity1 , 2 had increased @entity3876 , 1 had increased CK and 1 had increased CK-MB level compared to baseline. There were no symptomatic @entity299 which required monitorization and intervention. Statistically, there was no significant relationship between duration of @entity9433 administration and LVEF changes, QT distance prolongation, @entity3876 , CK and CK-MB level. CONCLUSIONS: @entity9433 is safe and has lower cardiac side effects than other TKIs. Thus @entity1370 is not a class effect of TKIs. Despite no clinically serious cardiac side effects of @entity9433 were observed in this study, the incidence of cardiac side effects is higher than previously reported @entity9433 studies.

Evaluation of cardiac safety of XXXX therapy for c-erbB2 amplified metastatic @entity0 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity6023 :: ('MESH:D043823', 'Chemical') :: ['taxanes'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine'] @entity9433 :: ('MESH:C490728', 'Chemical') :: ['Lapatinib', 'lapatinib'] @entity3876 :: ('4879', 'Gene') :: ['BNP', 'brain natriuretic peptide'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac problems', 'cardiac events'] @entity1162 :: ('MESH:D008133', 'Disease') :: ['QT prolongation'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity', 'Cardiac toxicity']
@entity9433 :: (MESH:C490728,Chemical) :: ['lapatinib']
